[Preliminary study of guacetisal in chronic bronchitis].
A single-blind, between-patients trial was run on two randomly formed groups of 15 hospitalised male patients with chronic obstructive bronchitis, carefully selected to rule out excessive interference on the part of other pathologies or lund complications, in which 3 tablespoonfuls a day Broncaspin suspension were compared with the same dose of a recognised commercial preparation composed by sodium thymosulphonate, ammonium acetate, codeine, and tincture of datura. The clinical and instrumental data showed that Broncaspin had greater therapeutic activity. The local and general tolerability of the two preparations was uneceptionable.
D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D004417:Dyspnea / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012119:Respiration / Q000187:drug effects; D013147:Spirometry
D001241:Aspirin; C023557:guacetisal
Studio preliminare del guacetisal nella bronchite cronica.